Send to

Choose Destination
Tuberc Respir Dis (Seoul). 2015 Oct;78(4):315-20. doi: 10.4046/trd.2015.78.4.315. Epub 2015 Oct 1.

The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib.

Author information

Division of Pulmonary, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
Department of Radiology, Chungnam National University Hospital, Daejeon, Korea.
Department of Preventive Medicine, Chungnam National University Hospital, Daejeon, Korea.



The efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy can be measured based on the rate of treatment response, based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria or progression-free survival (PFS). However, there are some patients harboring sensitive EGFR mutations who responded poorly to EGFR-TKI therapy. In addition, there is variability in the PFS after EGFR-TKI treatment.


We performed a retrospective analysis of the medical records of 85 patients with non-small cell lung cancer, who had achieved a stable disease or better response at the first evaluation of treatment response, after receiving a 2-month course of gefitinib. We calculated the tumor shrinkage rate (TSR) by measuring the longest and perpendicular diameter of the main mass on computed tomography before, and 2 months after, gefitinib therapy.


There was a significant positive correlation between the TSR and PFS (R=0.373, p=0.010). In addition, a simple linear regression analysis showed that the TSR might be an indicator for the PFS (B±standard error, 244.54±66.79; p=0.001). On univariate analysis, the sex, histologic type, smoking history and the number of prior chemotherapy regimens, were significant prognostic factors. On multivariate regression analysis, both the TSR (β=0.257, p=0.029) and adenocarcinoma (β=0.323, p=0.005) were independent prognostic factors for PFS.


Our results showed that the TSR might be an early prognostic indicator for PFS in patients receiving EGFR-TKI therapy.


Carcinoma, Non-Small Cell Lung; EGFR Tyrosine Kinase Inhibitor; Gefitinib; Progression-Free Survival

Supplemental Content

Full text links

Icon for The Korean Academy of Tuberculosis and Respiratory Diseases Icon for PubMed Central
Loading ...
Support Center